Promoting research partnerships to improve veterans’ health

NAVREF is proud to recognize Cohen Veterans Bioscience as our Champion Sponsor

NAVREF News Center

  • 8 Apr 2019 3:05 PM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $10 million (M) to the Department of Defense (DoD) Melanoma Research Program (MRP)to support innovative, high-impact melanoma research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The MRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 MRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    The FY19 MRP Focus Areas are listed below:

    • Precursor Lesions, Melanomagenesis, Host Factors, and the Tumor Microenvironment (e.g., melanoma instigators, ultraviolet [UV] exposure, other instigators)
    • Melanoma Primary Tumor Evolution (e.g., dormancy, heterogeneity, metabolism, epigenetic dysregulation, cell death)
    • Therapeutic Prevention
    • Minimal Residual Disease
    • Rare Melanomas (e.g., uveal, acral, leptomeningeal disease, pediatric, adolescent and young adult [AYA], mucosal)

    The MRP challenges the research community to redefine the concept of prevention and has issued a FY19 MRP Challenge Statement that should be considered when responding to the FY19 MRP Focus Areas and funding opportunities.

    https://cdmrp.army.mil/pubs/press/2019/19mrppreann

    Concept Award

    Investigators at or above postdoctoral fellow (or equivalent)

    ·        Supports the exploration of highly innovative, untested, potentially groundbreaking concepts in melanoma.

    ·        Emphasis is on Innovation.

    ·        Preliminary data is strongly discouraged.

    ·        Clinical trials are not allowed.

    ·        Blinded review.

    ·       Maximum funding of $75,000 for direct costs (plus indirect costs)

    ·       Maximum period of performance is year

     

    Idea Award

    Independent investigators with a faculty-level appointment (or equivalent)

    ·        Preproposal is required; application submission is by invitation only.

    ·        Supports new ideas that represent innovative, high-risk/high-gain approaches to melanoma research.

    ·        Emphasis on Innovation and Impact

    ·        Preliminary data are not required.

    ·        Clinical trials are not allowed.

    ·       Maximum funding of $300,000 for direct costs (plus indirect costs)

    ·       Maximum period of performance is years

     

    Team Science Award

    At least two and up to three investigators must partner in one overarching multidisciplinary research study.

    Initiating Principal Investigator (PI):

    Independent investigators at or above the level of Associate Professor (or equivalent).

    Partnering PI: Independent investigators at or above the level of Assistant Professor (or equivalent).

    Post-doctoral fellows are not eligible to be partnering PIs.

    ·      Preproposal is required; application submission is by invitation only.

    ·      Supports new or existing partnerships between two or three independent investigators focusing research across the whole research spectrum.

    ·      Investigators are expected to demonstrate within the application, the synergistic components (i.e., leveraging disciplines, expertise or critical resources) that will significantly advance the project such that the research outcomes as a whole will be realized rapidly and efficiently and could not otherwise be accomplished through independent efforts of a single investigator.

    ·      Emphasis on Synergy, Multi-disciplinary research, and Impact

    ·      Inclusion of an independent early career investigator is encouraged.

    ·      Inclusion of at least one military or U.S. Department of Veterans Affairs (VA) investigator is encouraged.

    ·      Preliminary data are required.

    ·      Clinical trials are not allowed.

    ·      Maximum funding of $700,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 3 years

     

    Translational Research Award

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    ·      Preproposal is required; application submission is by invitation only.

    ·      Supports studies aiming to leverage existing biobanks, biorepositories, ongoing or completed clinical trials to address a translational question or problem in melanoma.

    ·      Emphasis on Translation and Impact.

    ·      Inclusion of DoD or VA participation is encouraged.

    ·      Preliminary data is required.

    ·      Clinical trials are not allowed.

    ·      Maximum funding of $600,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 3 years

     

    A pre-application (letter of intent or pre-proposal) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the MRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 5 Apr 2019 1:40 PM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $3 million (M) to the Department of Defense Bone Marrow Failure Research Program (BMFRP)to support scientifically meritorious research focused on BMF diseases.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    FY19 BMFRP Program Announcement and General Application Instructions for the following award mechanism are posted on the Grants.gov website.

    https://cdmrp.army.mil/funding/bmfrp

     

    Idea Development Award – Preproposal due date June 6, 2019

    Established Investigators: 

    • Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from first faculty appointment (or equivalent) at the time of the application submission deadline are eligible.

    Early Career Investigators:

    • Investigators at the level of Assistant Professor (or equivalent) and less than 10 years from his/her first faculty appointment (or equivalent) at the time of application submission deadline are eligible.

     

    ·         Pre-application is required; full application submission is by invitation only.

    ·         Supports innovative ideas and high-impact approaches based on scientifically sound evidence in order to move toward the vision to understand and cure bone marrow failure (BMF) diseases.

    ·         Strong BMF research team.

    ·         May include relevant preliminary data.

    • Clinical trials will not be supported.

    ·         The maximum allowable funding for the entire period of performance is $325,000 in direct costs (plus indirect costs).

    • The maximum period of performance is 2 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the BMFRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 5 Apr 2019 1:39 PM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Vision Research Program (VRP)to support impactful military-relevant vision research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The VRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 VRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    Applications submitted to the FY19 VRP must address at least one of the following Focus Areas:

    • Eye injury or visual dysfunction as related to a military-relevant traumatic event.  Examples of military-relevant trauma may include, but are not limited to:

            Blast, blunt, thermal, or chemical trauma

            Trauma caused by directed energy weapons such as laser, microwaves, and particle beams

    • Diagnosis and treatment of eye injuries in austere environments and prolonged field care settings

    https://cdmrp.army.mil/pubs/press/2019/19vrppreann

    Focused Translational Team Science Award (FTTSA)

    ·         Overall Lead Principal Investigator (PI) must be an independent investigator at or above the level of Associate Professor (or equivalent) with experience in developing and running large-scale initiatives.

    ·         Leaders of individual projects may be independent investigators at all academic levels (or equivalent).

    Preproposal is required; application submission is by invitation only.

    ·        Supports a team initiative that leverages the strengths of investigators specializing in different fields to address an overarching scientific challenge or question and fundamentally advance the understanding and treatment of military-relevant vision trauma.

    ·        Overarching Challenge

    Investigators are encouraged to:

            Consider barrier(s) to and/or gap(s) in the understanding, prevention, diagnosis, mitigation, and/or treatment of eye injury or visual dysfunction associated with a military-relevant trauma and envision what may be achievable in 10 to 15 years.

            Identify, based on the long-term vision, what should and can be achieved in the near term.

            Design projects and research teams around these considerations.

    ·        Research Projects

            The team science proposal shall include at least three (3) but no more than five (5) distinct research projects that together form a concerted and synergistic effort that advances a solution beyond what would be possible through individual efforts.

            Preliminary data to support the feasibility of each project are required.

            May include, as a portion of the proposed research, a pilot clinical trial component that collects preliminary data to support the feasibility, rationale, and design of subsequent clinical trials.

    ·        Research Team

            The overall lead PI must have demonstrated success in leading large collaborative research projects.

            The overall lead PI must devote a minimum of 20% effort.

            Project leader of each of the complementary and synergistic research projects must be an independent investigator with strong qualifications.

            Must have a detailed Implementation Plan for participating research groups to coordinate efforts, facilitate collaboration, and create synergy

            Maximum funding of $5,000,000 for direct costs (plus indirect costs)

            The maximum period of performance is years.

     

    Investigator-Initiated Research Award (IIRA)

    Independent investigators at all academic levels (or equivalent).

    Preproposal is required; application submission is by invitation only.

    ·        Supports studies that will yield highly impactful discoveries or major advancements in research and/or patient care.

    ·        Funding Level 1supports exploratory, high-risk/high-reward research in the earliest stages of development.

            Research must have the potential to yield new avenues of investigation, such as new approaches, new research tools, or new paradigms.

            While no preliminary data is required, applicants must provide solid rationale of the research idea.  The investigating team must have sufficient expertise to test the idea.

            Applications in the following areas are encouraged:

            Pathobiology underlying TBI-associated visual dysfunction

            Assessment, diagnosis, or treatment in prolonged field care settings

            Mechanism of injury for visual system trauma secondary to directed energy

    ·        Funding Level 2supports the advancement of more mature research that has the potential to make significant advancements toward clinical translation.

            Preliminary data supporting the readiness and feasibility of the proposed research is required. 

    ·        PI is responsible for selecting the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the stage of the research project, rather than the amount of the budget.

    ·        Clinical trials are not allowed

    Funding Level 1:

    ·         Maximum funding of $260,000 for direct costs (plus indirect costs)

    ·         The maximum period of performance is years.

     


    Funding Level 2:

    ·         Maximum funding of $500,000 for direct costs (plus indirect costs)

    ·         The maximum period of performance is 3 years.

     

    Translational Research Award (TRA)

    Independent investigators at all academic levels (or equivalent).

    Preproposal is required; application submission is by invitation only.

    ·        Supports translational research that moves promising laboratory research into clinical applications.

    ·        It is expected that an IND or IDE application will be submitted during or by the end of the period of performance.

    ·        Expansion of a highly impactful research project that was previously funded through a VRP funding opportunity is encouraged but not required.

    ·        Preliminary data required.

    ·        May include, as a portion of the proposed research, a pilot clinical trial component that collects preliminary data to support the feasibility, rationale, and design of subsequent clinical trials.

    ·         Maximum funding of $750,000 for direct costs (plus indirect costs)

    ·         The maximum period of performance is years

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://ebrap.org/.  For more information about the VRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 5 Apr 2019 11:41 AM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $6 million (M) to the Department of Defense Multiple Sclerosis Research Program (MSRP) to support pioneering concepts and high-impact research that are relevant to the prevention, etiology, pathogenesis, assessment, and treatment of multiple sclerosis (MS) to ultimately lessen its personal and societal impact.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

     

    FY19 MSRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

     

    Applications submitted to the FY19 MSRP must address at least one of the following Focus Areas:

    1.            Factors That Promote Central Nervous System Regenerative Potential in Demyelination

    Supports innovative mechanistic studies and translational approaches to promote axonal protection, regeneration, or remyelination in MS and/or relevant experimental models. 

    Note:  Studies addressing the following topics will not be considered for funding: developmental myelination, dysmyelination, blood-brain barrier permeability, basic mechanisms of demyelination, neurodegeneration, or inflammatory mechanisms and anti-inflammatory therapeutic strategies that limit tissue injury secondarily.

    2.            Correlates of Disease Activity and Progression in MS

    Supports the identification and/or validation of correlates of disease activity and progression using pre-existing specimens and/or data acquired from well-characterized, adequately controlled, and sufficiently powered patient cohorts.

    Note:  The study must leverage pre-existing specimens and/or data that are available at the time of application submission; collection of a single set of specimens and/or data collected at one additional time point from participants in the existing cohort is allowed.

    3.            Biology and Measurement of MS Symptoms

    Supports studies on the biology and measurement of MS symptoms, which may include pain, fatigue, depression, anxiety, loss of bladder control, impaired mobility, and cognitive, motor, visual, or sexual dysfunction. 

    Note:  Studies of disease-modifying or regenerative therapies that secondarily impact MS symptoms will not be considered for funding under this Focus Area.

     

    https://cdmrp.army.mil/funding/msrp

     

     

    Exploration – Hypothesis Development Award - Preproposal is due May 21, 2019

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    *         Pre-application submission is required; application submission is by invitation only.

    *         Supports initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the MS research field.

    *         Preliminary and/or published data not required.

    *         Clinical trials are not allowed.

    *         Anticipated that budgets will not exceed $150,000 in direct costs (plus indirect costs)

    *          Period of performance not to exceed 2 years.

     

    Investigator-Initiated Research Award - Preproposal is due May 21, 2019

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    *         Pre-application submission is required; application submission is by invitation only.

    *         Supports highly rigorous, high-impact research projects that have the potential to make an important contribution to multiple sclerosis (MS) research and/or patient care.

    *         Preliminary and/or published data are required.

    *         Clinical trials not allowed.

    *         Anticipated that budgets will not exceed $600,000 in direct costs (plus indirect costs)

    *         Period of performance not to exceed 3 years.

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP home page at https://eBRAP.org.  For more information about the MSRP or other CDMRP-administered programs, please visit the CDMRP website https://cdmrp.army.mil.

     

    Point of Contact:

     

    CDMRP Help Desk

    301-682-5507

    help@eBrap.org

  • 4 Apr 2019 1:33 PM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $6 million (M) to the Department of Defense Tuberous Sclerosis Complex Research Program (TSCRP) to support innovative, high-impact TSC research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    FY19 TSCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

    Focus Areas:  The goal of the FY19 TSCRP is to fund exploratory, pioneering, and transformative science that promotes discoveries in tuberous sclerosis complex (TSC), from mechanistic insights to clinical application, by supporting new ideas and investigators for the benefit of Service members, their beneficiaries, and the American public.  Within this context, the FY19 TSCRP encourages applications that address the critical needs of the TSC community in one or more of the following FY19 Focus Areas:

    ·         Eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of TSC signaling pathways

    ·         Preventing epilepsy, improving treatment, and mitigating comorbidities associated with TSC-related seizures

    ·         Understanding the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact through pharmacological or nonpharmacological interventions

    ·         Advancing clinical trial readiness through development of biomarkers, clinical endpoints, clinical pharmacokinetic/pharmacodynamic (PK/PD), patient selection and sample size determination, novel drug delivery, and treatment optimization

     

    https://cdmrp.army.mil/funding/tscrp

     

    Submission Deadline Extension

     

    Exploration – Hypothesis Development Award – Letter of Intent due July 9, 2019

    ·         Investigators at all academic levels (or equivalent), including postdoctoral fellows

    ·         Supports the initial exploration of innovative, high-risk, high gain, and potentially groundbreaking concepts in the TSC research field.

    ·         Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b)(4) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.

    ·         Preliminary data are not required.

    • ·         Clinical trials not allowed.

    ·         The maximum allowable funding for the entire period of performance is $150,000 in direct costs.

    ·         Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    ·         Maximum period of performance is year

     

    Idea Development Award – Letter of Intent due July 9, 2019

    Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent);

    Or

    New Investigators:  Independent investigator at or below the level of Assistant Professor (or equivalent); or Established independent investigator in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC.

    ·         Supports ideas that have the potential to yield high-impact findings and new avenues of investigation.

    ·         Preliminary data are expected.

    ·         Clinical trials not allowed.

    ·         New Investigator Option supports the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into a career in TSC research.

    • ·         Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately

    ·         The maximum allowable funding for the entire period of performance is $450,000 for direct costs.

    ·         Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    ·         Maximum period of performance is 3 years

     

    Clinical Translational Research Award – Letter of Intent due July 9, 2019

    • ·         Independent investigators at or above the level of Assistant Professor (or equivalent)

    ·         Supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including, diagnosis, prognosis, or treatment of TSC.

    ·         Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of PK/PD are of particular interest.

    ·         Preference will be given to studies that involve human samples, patients, or leverage existing clinical data and/or ongoing clinical studies. 

    ·         Preclinical studies may be appropriate but must include a clinical component.

    ·         Applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.

    ·         Projects that are exploratory and/or strictly animal research will not be considered for funding.

    ·         Preliminary data required.

    ·         The maximum allowable funding for the entire period of performance is $600,000 in direct costs.

    ·         Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    • ·         Maximum period of performance is 3 years

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism is also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the TSCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 2 Apr 2019 10:12 AM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $5 million (M) to the Department of Defense Tick-Borne Disease Research Program (TBDRP)to support innovative, high-impact tick-borne disease research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    FY19 TBDRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

    Applications submitted to the FY19 TBDRP must address at least one of the following specific Focus Areas in Lyme disease and other tick-borne diseases:

    • Diagnosis
    • o   Accurate diagnostics and biomarkers for Lyme disease and co-infections and/or other tick-borne diseases
    • o   Diagnostic biomarkers for Lyme disease that distinguish between active infection and previous exposure, and/or monitor response to treatment
    • Pathogenesis
    • o   Pathogenic mechanisms, including immune protection, for Lyme disease, other tick-borne diseases, and/or co-infections
    • o   Complex biology of Lyme borrelia in the host (beyond in vitro studies), including its survival, evasion of the host immune system, and subversion of the effectiveness of antibiotics
    • o   Underlying mechanisms of persistent symptoms associated with Lyme disease
    • Prevention
    • o        Safe and effective human vaccines for tick-borne diseases
    • o        Identification, validation, and/or improvement of tick-targeted prevention and control interventions
    • o        Ecology of understudied tick-borne disease vectors and reservoirs with emphasis on how it relates to human risk.
    • Treatment
    • o   Antibiotic combinations and/or therapeutic options for treating acute and persistent illness
    • o  

    https://cdmrp.army.mil/funding/tbdrp

    Investigator-Initiated Research Award – Preproposal; due May 22, 2017

    • Independent investigators at or above the level of Assistant Professor (or equivalent)
    • ·       To fund highly rigorous, high-impact studies that have the potential to make important contributions to Lyme disease and other tick-borne disease research, patient care, and/or quality of life.
    • ·       Applications should articulate both the short- and long-term impact of the proposed research, as well as the public health burden of the disease being addressed.
    • ·       Preliminary or published data to support feasibility are required.
    • ·       Promotes any phase of research from basic through translational, including preclinical studies in animal models or human subjects, as well as correlative studies associated with an existing clinical trial to establish proof-of-principle for further development in future studies; however, clinical trials are not allowed.
    • ·       Maximum funding of $650K for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    Idea Award – Preproposal due May 22, 2019

    • Independent investigators at or above the level of Assistant Professor (or equivalent)
    • ·       To fund conceptually innovative, high-risk/potentially high-reward research in the early stages of development that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals affected by Lyme disease and/or other tick-borne illnesses.
    • ·       Applications should articulate the qualities that make the research innovative (not merely an incremental advance), as well as the public health burden of the disease being addressed.
    • ·       Preliminary data that are relevant to the proposed research project are encouraged, but not required.
    • ·       Clinical trials are not allowed.
    • ·       Maximum funding of $300K for direct costs (plus indirect costs)
    • Maximum period of performance is 2 years

    Career Development Award – Letter of Intent due May 22, 2019

    • Principal Investigator (PI): 
    • Early-career research scientist or physician scientist within 10 years of completing terminal degree (excluding time in residency or on family medical leave) at the time of submission, working to become independent investigators who exhibit a strong desire to pursue careers in tick-borne disease research; time spent as a postdoctoral fellow is not excluded
    • Mentor:  Independent investigators at or above the level of Associate Professor (or equivalent); must have a proven funding and publication record in tick-borne disease research
    • The PI and Mentor do not need to be located at the same organization.
    • To fund early-career investigators to conduct impactful research under the mentorship of an experienced tick-borne disease researcher.
    • Career Development Plan is required.  Plan should be prepared with appropriate guidance from the Mentor, should clearly articulate a strategy for acquiring the necessary skills, competence, and expertise to establish a career at the forefront of tick-borne disease research, and should outline how the PI will gain experience in tick-borne disease research.  PI’s institution must demonstrate a commitment to the PI through a minimum of 75% protected time for tick-borne disease research.
    • ·       Preliminary data are not; however, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated.
    • Clinical trials are not allowed.
    • ·       Maximum funding of $250K for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://ebrap.org/.  For more information about the TBDRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil/).

    Point of Contact:

    CDMRP Help Hesk
    301-682-5507
    help@eBrap.org


  • 1 Apr 2019 12:44 PM | Anonymous member (Administrator)


    WASHINGTON, DC - If you are reading this sentence, Happy April Fools Day from NAVREF! But guess what? This isn't necessarily all a joke either! NAVREF is proud to truly and honestly announce that for the 2019-2020 membership renewal year, NAVREF dues will undergo an unprecedented overall reduction.

    So how much of a reduction are we talking about? The new maximum dues amount will be capped at $10,000 which will immediately reduce dues for the 13 largest NPCs based on last year's renewal information. ALL other NPCs will be receiving a 10% cut clear across the board.

    How long will the dues reduction be in place? As of right now NAVREF is anticipating a minimum of 3 years guaranteed reduction with the goal to keep the cut permanently. Your continued support over the past 27 years has placed NAVREF in a formidable position with healthy reserves which we are now turning into a member benefit for all of our members.

    Have questions? We bet you do. Submit your questions to Hawk @ htran@navref.org

  • 29 Mar 2019 10:18 AM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $10 million (M) to the Department of Defense Hearing Restoration Research Program (HRRP)to support promising, necessary research for treatment of burdensome and very prevalent auditory system injury.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The HRRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 HRRP Program Announcement and General Application Instruction for the following award mechanism are anticipated to be posted on the Grants.gov website in May 2019.  Pre-application and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the government.

    https://cdmrp.army.mil/pubs/press/2019/19hrrppreann

    Focused Research Award

    Independent investigators at all academic levels (or equivalent) are eligible to submit applications.

    Preproposal is required; application submission is by invitation only.

    ·      Supports promising research that has the potential to make, or lead to, significant advancement in hearing restoration.

    ·      Must address at least one of FY19 HRRP Focus Areas:

    • Develop or validate techniques/methods to assess or diagnose auditory dysfunction as related to synaptopathy, hidden hearing loss, and central auditory processing disorders.  For example: diagnostic tests that help differentiate sensory, neural, synaptic, and central processing disorders; diagnostic tools for use in forward or remote deployed settings; treatments for the various types of damage that result in auditory dysfunction.
    • Accelerate translation of biological regeneration/repair mechanisms into therapies that restore auditory function.
    • Develop reliable in vitro human models for evaluating hearing restoration therapies.  

    ·      It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.

    ·      Funding Level 1 requires preliminary data to support the rationale of the research idea and the investigating team’s expertise in the subject area.

    ·      Funding Level 2 requires preliminary data to support the feasibility of the proposed research strategy.

    ·      Funding Level 2 may include a pilot clinical trial where limited clinical testing of a novel intervention is conducted to inform the feasibility, rationale, and design of subsequent clinical trials.

    Tinnitus or vestibular-related research is excluded.

    Funding Level 1:

    ·        Maximum funding of $250,000 for direct costs (plus indirect costs)

    ·        The maximum period of performance is 2 years.

    Funding Level 2:

    ·        Maximum funding of $1M for direct costs (plus indirect costs)

    ·        The maximum period of performance is 3 years.

    Funding Level 2 with Pilot Clinical Trial Option:

    ·        Maximum funding of $1.25M for direct costs (plus indirect costs)

    The maximum period of performance is 3 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the HRRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 29 Mar 2019 10:18 AM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $30 million (M) to the Department of Defense Spinal Cord Injury Research Program (SCIRP)to support innovative, high-impact spinal cord injury research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The SCIRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 SCIRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in April 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    For FY19, SCIRP encourages applications that address the critical needs of SCI research and patient care in one or more of the following FY19 Focus Areas:

    • Neuroprotection
    • Biomarkers
    • Bladder dysfunction,  bowel dysfunction and neuropathic pain
    • Psychosocial issues relevant to SCI in  individuals with SCI or their caregivers
    • Rehabilitation and regeneration

    https://cdmrp.army.mil/pubs/press/2019/19scirppreann

    Clinical Trial Award

    Independent investigators at all academic levels (or equivalent)

    ·    Preproposal is required; application submission is by invitation only.

    ·    Fund Phase 0, I, or II clinical trials with the potential to have a major impact on treatment or management of spinal cord injury (SCI) and its consequences.

    ·    Applications must include at least two SCI consumer advocates as members of the research team.

    ·    Preclinical data required for all clinical trial applications.

    ·     Maximum funding of $3M for direct costs (plus indirect costs)

    ·      Maximum period of performance is years

    Investigator-Initiated Research Award

    Independent investigators at all academic levels (or equivalent)

    ·    Preproposal is required; application submission is by invitation only.

    ·    Fund SCI-related research that has the potential to make an important contribution to SCI research and/or patient care.

    ·  Preliminary data required.

    ·  Clinical trials not allowed.

    ·     Maximum funding of $500,000 for direct costs (plus indirect costs)

    ·  Maximum period of performance is 3 years.

    Translational Research Award

    Independent investigators at all academic levels (or equivalent)

    ·      Preproposal is required; application submission is by invitation only.

    ·      Fund studies that accelerate the movement of promising ideas in SCI research into clinical applications.

    ·      Applications must include at least one SCI consumer advocate as a member of the research team.

    ·      Preliminary data required

    The SCIRP TRA may include a pilot clinical trial as part of the proposed research where limited clinical testing of a novel intervention or device is necessary to inform the next step in the continuum of translational research.

    ·     Maximum funding of $1.25M for direct costs (plus indirect costs)

    ·      Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the SCIRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 29 Mar 2019 10:17 AM | Anonymous member (Administrator)

    The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP)to support research of exceptional scientific merit in the area of kidney cancer.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The KCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 KCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    https://cdmrp.army.mil/pubs/press/2019/19kcrppreann

    Concept Award

    Investigators at all academic levels

    • Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer
    • Emphasis on innovation
    • Funding for clinical trials not allowed
    • Preliminary data not allowed
    • Blinded review
    • Maximum funding of $75,000 for direct costs (plus indirect costs)
    • Maximum period of performance 1 year

    Idea Development Award

    Established Investigators: 

    Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or

    Early Career Investigators:

    Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible

    ·      Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer

    ·      Preliminary data required

    ·      Innovation and Impact the most important review criteria

    ·      Funding for clinical trials not allowed

    • FY19 KCRP Areas of Emphasis strongly encouraged
    • Maximum funding of $400,000 in direct costs (plus indirect costs)
    • Maximum period of performance 2 years

    Translational Research Partnership Award

    Investigators at or above the level of Assistant Professor (or equivalent)

    ·      Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications

    ·     Supports translational correlative studies

    ·      Preliminary data required

    ·      Funding for clinical trials not allowed

    ·     Maximum funding of $600,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance 3 years

    Kidney Cancer Academy Dean Award

    Dean must be an independent, established kidney cancer researcher with a record of kidney cancer research funding and publications in peer-reviewed journals

    ·      Supports visionary individuals who are established kidney cancer researchers with a strong record of mentoring and commitment to leadership

    ·      Academy Dean will oversee an interactive virtual academy of ECIs and their designated mentors, facilitate regular interactive communication among all Academy members, and assess the research progress and career progression of the ECIs

    ·     Maximum funding of $500,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance 4 years

    Kidney Cancer Academy Early Career Investigator Award

    Within 3 years of last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent, as of full application submission deadline

    Letter attesting to eligibility required

    ·      Supports addition of new ECIs to the unique, interactive virtual academy that provides intensive mentoring, national networking, and a peer group for junior faculty

    ·      ECIs whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply

    ·      Requires Designated Mentor who is an experienced kidney cancer researcher with kidney cancer funding

    ·      Designated Mentor not required to be at the same institution as the ECI

    ·      Preliminary data required

    ·      Clinical trials allowed

    ·     Maximum funding of $725,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance 4 years

    Clinical Consortia Award

    Independent Investigators at or above the level of Assistant Professor (or equivalent)

    ·      Supports development of a consortium that will facilitate rapid execution of collaborative Phase II or Phase I/II clinical trials to bring to market high-impact, novel therapeutic interventions that will ultimately and significantly decrease impact of kidney cancer

    ·      Funds may not be used for research or development of clinical protocols

    ·      Trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer encouraged

    ·      One (1) Coordinating Center and three (3) Clinical Trial Sites will be selected and be jointly responsible for proposing, selecting, and conducting trials

    ·      Sites must provide plans for accruing patients from populations disproportionately affected by kidney cancer

    ·      Consortium expected to achieve financial self-sufficiency, such that operations can continue after the award ends

    Coordinating Center:

    ·      Maximum funding of $3,000,000 for direct costs (plus indirect costs)

    ·     Maximum period of performance 3 years

    Clinical Trial Sites:

    ·     Maximum funding of $600,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software